KTTA logo

PASITHEA THERAPEUTICS CORP

KTTANASDAQ
🏆 #4825 by market capEarnings Nov 11US Equity
$0.49▲ $0.01 (+3.02%)
Market closed · at close
🔔
Track KTTA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.0%
7d▼ 3.8%
14d▲ 0.8%
30d▼ 15.1%
ytd▼ 62.0%
1y▼ 31.3%
🏦Market Cap
$17M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
44
Weak

Trading Snapshot

Day Range
$0.49 – $0.50
52-Week Range
$0.28 – $2.06
Volume
$2.42B
Avg Volume
$2.09B
Shares Outstanding
33.4M
Next Earnings
Nov 10, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$455,345
P/E Ratio
-0.2
P/S Ratio
0.0x
EPS (TTM)
$-3.03
Dividend Yield
0.00%
Dilution (1yr)
+541.5%

Why Investors Own KTTA

  • ✓High-growth profile — revenue up +5.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 40% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KTTA logo

PASITHEA THERAPEUTICS CORP

KTTA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$21M▲ +46.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$15M▲ +9.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
7.0M▲ +541.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$55M▲ +$48M YoY
StockOtter · stockotter.space

About PASITHEA THERAPEUTICS CORP

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Bloomberg·2h ago

PASITHEA THERAPEUTICS CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift KTTA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

PASITHEA THERAPEUTICS CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.